• Earlier studies show that CYB004 via inhalation may solve existing challenges and support a clinical path forward for this important therapeutic
• Cybin is currently developing CYB004 for the treatment of anxiety disorders
• The new chemical entity is covered by a patent issued earlier this year

Cybin (NEO: CYBN) (NYSE American: CYBN) has released data from a pharmacokinetic study focused on evaluating CYB004, the company’s proprietary deuterated dimethyltryptamine (“DMT”) molecule (https://ibn.fm/nyCj8). The study analyzed delivery methods of CYB004, and showed initial data indicates significant advantages over Intravenous (“IV”) and Inhaled DMT. “In many studies, DMT has shown to be a promising and effective psychedelic for the treatment of mental health issues,” said Cybin CEO Doug Drysdale. “However, known side effects like disorientation and anxiety and its mode of administration have historically hindered its use and availability. CYB004 via inhalation may solve these challenges and finally support a clinical path forward for this important therapeutic.” According to the report, inhaled CYB004 showed significant advantages over both IV DMT and inhaled DMT, including longer duration of action and improved bioavailability. The study also indicated that inhaled CYB004 showed an onset of effect and dose profile similar to IV DMT. “These data may support the potential for inhalation as a viable and well-controlled delivery system of therapeutic psychedelics,” the announcement states, noting that Cybin is currently developing CYB004 for treatment of anxiety disorders. Specifically, the company reported that, based on preclinical results, inhaled CYB004 demonstrated:

• Approximately 2,000% improved bioavailability compared with orally administered DMT, which is known to have limited to no oral bioavailability
• Approximately 41% improved bioavailability compared with inhaled DMT
• Approximately 300% longer duration of effect when compared with IV DMT, indicating potential to extend the therapeutic window
• Rapid onset of effect and low variability equivalent to IV DMT

A new chemical entity, CYB004 is covered by a patent issued by the U.S. Patent and Trademark Office earlier this year. The patent allows claims that include a range of deuterated forms of DMT and 5-MeO-DMT. The composition of matter patent is expected to expire in 2041 before consideration of any patent term extensions. “As part of Cybin’s overall mission to create safe and effective psychedelic-based therapeutics, inhaled CYB004 is being developed to potentially overcome the limitations of IV DMT and become an important treatment option for anxiety disorders for patients and physicians,” stated Drysdale. He also noted that the company plans to submit a regulatory filing for a pilot study in the coming weeks. “Cybin’s approach to psychedelic drug development enables the control of many biological factors, including improving the way a drug is metabolized and managing some adverse effects. “In its natural form, DMT is unstable and not orally bioavailable,” Drysdale concluded. “Based on these preclinical studies, we believe CYB004 has the potential to overcome these issues. These results also provide strong evidence that an inhaled delivery mode may be able to address the limitations of IV DMT and could be widely applicable to a variety of psychedelics.” Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Clean energy solutions innovator FuelPositive Corp. is developing a scalable, containerized, modular means of producing green ammonia for customers in the agriculture industry
• The agriculture industry uses 80 percent of the current global supply of ammonia for fertilizer
• FuelPositive’s IP is designed to produce 300 kilograms per day of liquid anhydrous carbon-free ammonia — the amount needed to fertilize and power a 2,000-acre farm
• FuelPositive is initially targeting Canadian farmers as the customers for its green ammonia solution, and has established research partnerships to determine how to most effectively roll out its modules in order to meet farmers’ needs

Clean energy solutions innovator FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), is nearing the rollout of its first onsite demonstration system for producing green, hydrogen-dense anhydrous ammonia, with an initial goal of helping the agricultural industry buffer against the difficulties of supply chain interruptions and improving the industry’s impact on the climate. Green ammonia is gaining gravitas as a clean energy solution to environmental pollution that is believed to be altering climates worldwide. Chemical & Engineering News describes the process pioneered a century ago to produce ammonia from hydrogen and atmospheric nitrogen as perhaps the biggest global problem ever solved by chemistry, due to ammonia’s utility as high volume-producing fertilizer and now as a means of producing hydrogen for energy or for use in energy generation in its own right. “Up to this point, we have made a business by selling the nitrogen value of the molecule,” ammonia producer CF Industries’ CEO Tony Will told the magazine (https://ibn.fm/cYCpk). “What’s really exciting about this is now there is an opportunity and a market that values the hydrogen portion of the molecule.” FuelPositive is helping to pioneer such scientific development by rolling out its scalable, containerized “plant-in-a-box” that uses a carbon-free process to make pure green ammonia. The company’s first demonstration system will launch on a farm in Manitoba, Canada, later this year, followed by two additional demonstration systems in coming months (https://ibn.fm/CXxA5). The system is designed to produce 300 kilograms per day of liquid anhydrous carbon-free ammonia, which FuelPositive describes as the approximate amount needed to fertilize and power a 2,000-acre farm. The technology is already proven in the lab and the company is now moving it into real world application. “Ammonia can be produced with natural elements such as the sun, air and water, resulting in a sustainable output. Of course, since the plant operates on renewables, it needs a constant supply of energy, so the location needs to be considered carefully – it is best to build a green ammonia plant near the energy source to optimize the financial model,” one author states in a recent issue of Fertilizer Focus magazine (https://ibn.fm/E8uNZ). But the shipping container-sized models designed by FuelPositive for portability mean that the plant can effectively be delivered easily to the end user under a decentralized methodology that grants the end user a great deal of control over the product. In keeping with FuelPositive’s focus on serving the agricultural industry, which consumes 80 percent of the current global supply of ammonia for fertilizer, the company announced March 29 that Pollara Strategic Insights will become a corporate market research partner and University of Guelph (Ontario) associate research professor Leith Deacon will provide further advisement on data-based rural planning to help FuelPositive most effectively reach its target consumer (https://ibn.fm/Z46od). “It’s important to recognize that if you’re designing a product for farmers, you need to make sure the product is reflective of farmers’ realities. The only way to know what they need and want is to ask them. I’m excited to see that FuelPositive is engaging directly with farmers and taking its decision-making so seriously,” Deacon stated. “Our team has extensive experience in the agriculture space, especially in terms of sustainable and regenerative farming. We are conducting qualitative interviews and quantitative surveys across a robust sample of Canadian farmers to extract deep insights and direction for the Company to consider when making its decisions,” Pollara’s founder and chief strategist Don Guy added. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• The bitcoin 2022 convention took featured over 450 speakers, with more than 3,000 companies represented during the event
• LQwD currently has 10 active nodes on the Lightning Network – France, England, Sweden, Singapore, Italy, Indonesia, Germany, Ireland, India and the US
• By 2030, the Lightning Network could see more than 700 million users leading to as many as 364 trillion transactions per year

Presented by Cash App, the biggest bitcoin event in the world (bitcoin 2022) took place April 6-9, 2022, in Miami, Florida. The four-day event included Industry Day (April 6), the Main Convention (April 7 & 8), and the first-ever Bitcoin music festival Sound Money Fest (April 9). Over 35,000 attendees took advantage of the insight provided by over 450 speakers at the convention, which was sponsored by over 400 investors with more than 3,000 companies represented. The packed agenda included Q&A sessions, strategy, and even a Lightning Network Report presented by Torbjørn Bull Jenssen, CEO of Nordic cryptocurrency powerhouse Arcane Crypto (https://ibn.fm/KZ23S). Expanding at a fast rate, the Lightning Network has changed the way that transactions are handled across the blockchain. Many companies have leveraged technology that overlays the layer 2 payment protocol layered on top of a blockchain-based cryptocurrency like bitcoin or Litecoin. LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a financial technology company creating enterprise-grade infrastructure to drive bitcoin adoption, released a proprietary platform as a service (“PaaS”), https://lqwd.tech/, in November 2021, allowing users to send and receive payments quickly using the Lightning Network. LQwD has invested its own bitcoin in the Lightning Network – with 10 active nodes spanning multiple geographic locations. Currently, LQwD has nodes operating in France, England, Sweden, Singapore, Italy, Indonesia, India, Germany, Ireland, and the United States. Current LQwD Lightning Node statistics, as of April 25, 2022:

• US-West
  • Capacity: 5.689273640 BTC (US $224,462.72)
  • Channel Count: 106
• Ireland
  • Capacity: 0.380000330 BTC (US $14,992.41)
  • Channel Count: 8
• Germany
  • Capacity: 1.360000160 BTC (US $53,657)
  • Channel Count: 25
• Indonesia
  • Capacity: 1.835046080 BTC (US $72,399.3)
  • Channel Count: 35
• Italy
  • Capacity: 0.250000250 BTC (US $9,863.43)
  • Channel Count: 5
• Singapore
  • Capacity: 1.344596260 BTC (US $53,049.26)
  • Channel Count: 23
• Sweden
  • Capacity: 0.350000440 BTC (US $13,808.8)
  • Channel Count: 7
• England
  • Capacity: 0.470000150 BTC (US $18,543.23)
  • Channel Count: 11
• France
  • Capacity: 2.130782200 BTC (US $84,067.18)
  • Channel Count: 40
• India (launched April 19, 2022)
  • Capacity: 0.050000000 BTC (US $ 1,972.68)
  • Channel Count: 1

To follow LQwD’s presence on the Lightning Network, visit www.1ML.com. When the new nodes were released, CEO Shone Anstey shared the company’s insight, underlying that the launch firmly positions LQwD to increase its overall value on the network. “Being a leading Lightning Network infrastructure and transaction facilitator has a lot of value: First, Lightning Network’s early-movers (like us) are best positioned to strategically expand our position on the network,” Anstey explained (https://ibn.fm/MHaj1). “Second, the more nodes LQwD establishes worldwide; the more transactions can be routed through our node network. And each transaction represents a routing fee.” The Lightning Network has seen constant growth in the past year and is expected to continue this upward trend, along with the global cryptocurrency market. According to an October 2021 report by Arcane Research titled “State of Lightning,” the Lightning Network could see more than 700 million users by 2030, leading to as many as 364 trillion transactions per year. Meanwhile, the global cryptocurrency market is expected to reach US $4.94 billion by 2030, growing at a CAGR of 12.8% from US $1.49 billion in 2020. Growth drivers include the need for increased transparency in payment systems and the untapped potential within emerging economies (https://ibn.fm/ZKh3B). For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• Correlate will set up a 908-kW rooftop solar project at Continental Envelope’s Geneva, Illinois headquarters
• Once completed, this project will provide over 1.2 million kilowatt-hours of clean energy and power 20-25% of the facility’s overall energy needs
• Engineering work has already commenced on the project, with construction projected to start in the summer of this year
• Correlate’s management is confident that once done, this project will showcase what the company can do and how achievable energy forward-thinking is for manufacturing businesses of all kinds and sizes across the world

Since its inception, Correlate Infrastructure Partners (OTCQB: CIPI) has created an industry-leading energy solution and financing platform focusing on the commercial and industrial sectors. This stems from the fact that there is a significant untapped opportunity in these two areas, starting with the much-needed clean-energy upgrades necessary to achieve U.S. 2050 carbon goals. In an assessment conducted by the company, it has been established that, for the carbon goals to be achieved, at least 200,000 commercial buildings should be retrofitted every year until that date, representing a 5-10 time increase over the 2022 industry process run rate. In a move that seeks to bring the company closer to achieving this goal, it has partnered with Continental Envelop to set up a 908-kW rooftop solar project which, once completed, will power 20-25% of the facility’s overall energy needs. Continental Envelope manufactures 2 billion envelopes every year and counts some of the leading brands in the U.S. as clients, including Netflix, AT&T, Capital One, and American Express. The company’s headquarters, located in Geneva, Illinois, where the solar project will be located, is 84 years old, with the company itself being in operation since the 1930s (https://ibn.fm/QX2pL). Given its efforts to embrace and adopt clean energy, Continental Envelope has been termed one of the greenest envelope factories in the country. The move to install the rooftop solar project only seals that title and sets the company apart from its peers. Engineering work on the solar project kicked off on April 18, 2022, with construction estimated to start in the summer of this year. The project will feature 1667 solar energy modules with the capacity to produce over 545 watts each. Once done, the entire project will provide over 1.2 million kilowatt-hours of clean energy and offset over 18,849 tons of carbon dioxide over the next 20 years, according to the EPA’s Greenhouse Gas Equivalencies Calculator. “Correlate Infrastructure Partners is pleased to move forward with the Continental Envelope solar project, which will contribute to the modernization of their electricity generation supply and improve its sustainability,” noted Correlate’s Chief executive Officer (“CEO”), Todd Michaels. “We are grateful to partner with this innovative family business as we lead the printing and manufacturing industry toward clean, efficient, and renewable generation without compromising reliability,” he added. Correlate’s management is confident that this project will show how achievable energy forward-thinking is, not just for printing but also for manufacturing businesses worldwide. It also believes that it will showcase the company’s capacity to execute a project of this size, plan and create an innovative building health program of activities designed to set companies on the path toward Net-Zero. “This solution for Continental envelope is a demonstration of Correlate’s commitment to designing and building customer-centric energy projects that not only deliver profitable sustainability, but also leverage local and national incentives and technology like solar and storage to provide meaningful financial benefit to our customers’ bottom line,” noted Jason Loyet, the Director of Solar Energy & Storage with Correlate For more information, visit the company’s website at www.CorrelateInfra.com. NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• SPYR Inc., through its wholly owned subsidiary Applied Magix, develops and resells Apple ecosystem-compatible products
• Applied Magix enabled SPYR to enter the rapidly growing smart-home and smart-car markets
• SPYR offers a wide array of products such as MagixDrive, a secure video camera with iCloud storage, MagixBlock USB DataBlocker, MagixCharge Dual USB-C Car Charger, and more
• With these products, SPYR targets Apple’s following of loyal consumers, who have a limited selection of HomeKit-enabled products from which to choose

As the smart homes and smart cars markets heat up, generating much interest from consumers and manufacturers alike, they have attracted both established tech behemoths, including Amazon.com Inc. (NASDAQ: AMZN), Google Inc., Microsoft Corporation (NASDAQ: MSFT), Intel Corporation (NASDAQ: INTC), and Apple Inc. (NASDAQ: AAPL), as well as growing technology companies such as SPYR (OTCQB: SPYR). According to a recent editorial piece entitled “Smarter Homes, Smarter Cars, Smarter People,” SPYR, through its strategically acquired wholly-owned subsidiary Applied Magix Inc., is specifically focusing its attention on providing smart hardware and software products for Apple’s large following of loyal consumers (https://ibn.fm/6404o). In doing so, the company offers a solution to a problem that has seen Apple fall behind competitors such as Google and Amazon with its comparably limited portfolio of HomeKit-enabled products. HomeKit is Apple’s software framework – akin to Google Home (Google Assistant) and Amazon Alexa – that enables iOS and iPadOS devices to connect to and control smart-home appliances. Applied Magix, a registered Apple developer and reseller of Apple ecosystem-compatible products acquired in 2020, has enabled SPYR to selectively target Apple consumers, who are renowned for being extra passionate about the brand as well as their willingness to pay a premium for Apple’s quality products and seamless integration of the closed ecosystem. According to the latest statistics, this ecosystem comprises 1.8 billion active iPhones, an increase from 1.65 billion active iPhones in January 2021 (https://ibn.fm/GEnb3). The subsidiary’s first product, the MagixDrive, is an adapter that creates a wireless experience enabling users to enjoy all the perks of CarPlay, such as streaming services, Siri voice commands, navigation, apps, and more, without having to connect their phones to a cable. “This is a golden opportunity for Applied Magix to become front and center with Apple users, capture market share, and create a loyal following,” the Editorial reads. And to better improve these chances, Applied Magix is actively marketing MagixDrive through a commercial campaign, whose airing schedule was expanded in February to grow the product’s reach and visibility (https://ibn.fm/TLiHk). In addition to MagixDrive, Applied Magix also offers additional products, including a secure video camera with iCloud storage, MagixBlock USB DataBlocker, MagixCharge Dual USB-C Car Charger, and more (see below for a complete list). With these products, SPYR and Applied Magix target multiple multi-billion-dollar markets that are projected to continue growing well into the future. For instance, Grand View Research anticipates the global smart home security cameras market will grow at a 15.7% CAGR, reaching $11.89 billion by 2027 (https://ibn.fm/h1T6H). Likewise, Allied Market Research projects the global connected car market will grow to $225.16 billion by 2027, up from $63.03 billion in 2019, representing a 17.1% CAGR (https://ibn.fm/fHOoW). “SPYR and Applied Magix management, including a newly formed advisory board, are initially setting their sights on Apple consumers throughout North America and Europe, in other words, those with the largest profit potential, which should translate into corporate value. To reach these consumers, Applied Magix leverages strong relationships with third-party distributors and influences of Apple consumer products,” the Editorial reads. To view the full Editorial, please visit: https://ibn.fm/FBmke To listen to the Network News Audio broadcast covering the Editorial, please visit: https://ibn.fm/Gxxk4 For product information, please see the Applied Magix website at https://AppliedMagix.com, or specific product sites:

• MagixDrive Wireless CarPlay Adapter –https://appliedmagix.com/MagixDriveBundle
• HomeKit Secure Video Camera with iCloud Storage – https://appliedmagix.com/HomeKitCamera
• Multipurpose Sensor with Alarm –https://appliedmagix.com/HomeKitAlarmSensor
• Environment and Motion Sensor –https://appliedmagix.com/HomeKitMotionSensor
• Window and Door Contact Sensor – https://appliedmagix.com/HomeKitContactSensor
• MagixBlock USB DataBlocker – https://appliedmagix.com/MagixBlock
• MagixCharge Dual USB-C Car Charger – https://appliedmagix.com/MagixCharge

For more information, visit the company’s website at www.Spyr.com. NOTE TO INVESTORS: The latest news and updates relating to SPYR are available in the company’s newsroom at https://ibn.fm/SPYR

Explore the world of cannabis and navigate the immense networking opportunities offered at the O’Cannabiz Conference Expo & Awards from June 1-3, 2022. This event offers a phenomenal stage for traders, cultivators, marketers, regulators, researchers, and cannabis businesses in the region to get recognition on the global forum, amongst the stalwarts of the cannabis space. This year, the conference is being organized by O’Cannabiz Conference Expo & Awards as a physical event at the International Centre- Hall#5, Ontario, Canada, after being canceled last year due to COVID-19. The Conference and Expo will be held at the 50,000 sq. ft hall with 3500+ attendees networking in 70+ interactive sessions, with 180+ industry leaders speaking about cannabis trading, laws and regulations, the scope and future of industries, as well as the compliance in Canada. The participants will be welcomed by a Red Carpet Royalty Cocktail Reception, followed by a dinner and awards ceremony, and an after-party session with VIP networking for exhibitors, sponsors, and delegates. The event group is a pioneer in hosting high-tech events to open networking avenues among traders, businesses, enthusiasts, and government bodies across the entire spectrum of industries. The event will also showcase O’Cannabiz Industry Gala Awards, hosted by Gerry Dee, where the team will honor Tommy Chong with a Lifetime Achievement Award along w ith his celebrity interview. The next day is followed by exhibits and respective booths where cannabis industries and retailers can showcase their business ideas and get discovered by potential investors. Seek in-depth knowledge and insights from the spectacular line-up of speakers and become a part of engaging sessions where these influencers will discuss a plethora of topics across the entire spectrum of cannabis industries and trade. At the O’Cannabiz Conference Expo & Awards, the teams take up the initiative of connecting investors, traders, retailers, exhibitors, and regulators of cannabis use and trade over a common stage. They have organized global trade summit initiatives and are experienced to handle government entities and have worked with the Canadian government. The Conference will include sessions on the Psychedelic trade, its regulations, laws, and viability from a commercial standpoint. Attendees will also get an opportunity o to connect with investors, peers, and influencers during the networking breaks. They can leverage this opportunity to connect ad develop long-term ties with business associates and discover new prospects. To know more, please visit https://ocannabiz.com/.

Become a part of Canada’s #1 Cannabis Conference and Trade Show for a full-day immersive learning experience about Cannabis business and trade at the Lift Cannabis Business Conference on May 12, 2022. The business conference is a part of the 4-day Lift&Co. Expo Toronto 2022 that is being held at the Metro Toronto Convention Centre. The Cannabis Business Conference will be attended by cannabis business leaders from across North America and around the world and will feature speaker sessions and presentations to impart the latest intelligence on myriad aspects of the cannabis industry. Connect with the experts, innovators, regulators, and leaders of the cannabis business community, build long-term business ties, and get discovered by potential investors within this robust networking forum. The Lift Cannabis Business Conference commences at 9:00 am with opening remarks from Dr. Sherry Boodram, CEO & Co-Founder, CannDelta. Below is an at-a-glance agenda for the conference:

• World In Review: The rapidly-growing Canadian and global cannabis markets-opportunities, statistics and latest trends for 2022-2023.
• Next-Gen Spotlights: Discussion on two important product innovations in cannabis.

1. The Future is Coming Fast for Rapid Delivery Cannabis-How rapid delivery works, potential applications for patients and consumers, and what are the current roadblocks, business potential, and future.
2. The Progress Toward Odorless Cannabis-Research and results, future potential, consumer trends, and more.

• CSR Shift: Evolution of the cannabis business and its social impact-collaborations with non-profits, challenges with the current regulations, promoting responsible use, and promoting the safe and responsible use of cannabis.
• Economic Shift: Establishing an Industry panel for Innovation, Science, and Economic Development that includes members of the industry, regulators, and policymakers, who discuss and monitor the industry’s economic development needs and tackle challenges within the sector.
• Production and Profitability: Streamlining supply, demand, and business growth in a rapidly evolving market.
• Risk and Profitability: How current and emerging trends impact risk management and profitability.
• The Next Big New Product Category: Which new wellness products will hit the market?
• Craft and Premium: Best micro-producers and top shelf brands.
• Canada’s Cannabis Legislation Review: What to expect following the review.
• Competitive Strategy: Insights on winning competitive strategies in the cannabis sector.

The Lift Cannabis Business Conference represents an unmatched learning experience for both established and new businesses in the cannabis industry. Tickets for the conference also include lunch, a private reception on the evening of May 12, and access to all three days of the Lift&Co. Expo Exhibit Hall, May 13-15, 2022. To learn more, please visit https://liftexpo.ca.

• Acquired in January 2022, Artist Republik and FeaturedX, in conjunction with the Fan Pass Live artist platform, have created a 360 platform offering for music artists looking for independence from label control
• Artists are not the only ones benefiting from Friendable’s offering – fans are also gaining access to their favorite artists without the boundaries implemented by traditional record labels
• Friendable’s 360 offering allows artists to receive more revenue through fan subscriptions, ticket sales, tips, merchandise, and more
• Since launching the 360 platform, Friendable has seen consistent (and positive) growth across social media platforms, including a larger online presence

Major limitations exist in the music industry for independent artists trying to enter and make a name for themselves. In addition to the lack of support and overwhelming control by a music label, there are overwhelming amounts of fees that result in revenue loss, at times up to 90%. These strict contracts and financial burdens often make it hard for artists to find footing in the industry and can either hinder advancement or completely quash their dreams before they can try reaching them. Friendable (OTC: FDBL) is disrupting the music industry by offering music artists the first 360 artist platform for production, distribution, and marketing. In conjunction with Artist Republik and FeaturedX, the Fan Pass Live artist platform takes gatekeepers and intermediaries out of the equation, leaving artists 100% in control of their music careers. The Fan Pass Live artist platform offers an incentive for both artists and fans. Artists gain the benefits of:

• Music distribution and management
• Music production assistance
• Press release and Instagram promotion
• Digital storefront activation
• Artist marketplace for collaborators
• Merchandise, logo, and promotional design support
• Virtual concert booking and ticketing
• Mobile streaming services
• Livestreaming support
• Revenue from fan tips, monthly artist contests, merchandise, and ticket sales
• Access to fan data and performance analytics
• Monthly artist contests
• NFT development and metaverse performances (coming soon)

Fans get the opportunity to experience:

• Exclusive access into the artists’ lives
• Browse for upcoming events
• Backstage access before, during, and after an event
• A single dashboard to view notifications, discussions, and artists
• Real-time interactions through livestream
• Exclusive videos and one-on-ones
• Behind-the-scenes access to videos and music performances
• Access to exclusive artist merchandise

In January 2022, the Fan Pass Live artist platform became the first 360 platform offering for music artists following the successful acquisition of Artist Republik and FeaturedX. Since then, the 360 platform offering has seen positive growth. “From social media to revenue and user increases, as well as steady growth in key categories, it tells us everything we need to know about the path we are on as a Company, platform, team, and community of fledgling artists, fans and investors all seeking to facilitate the launch and discovery of artists worldwide as we build a brand that stands alongside each one,” CEO Robert A. Rositano Jr. said in a recent press release (https://ibn.fm/FA7H3). (https://ibn.fm/h2pBn). Besides growth metrics, Friendable highlighted all industry stressors and the benefits of having the 360 platform available for independent artists in their newest corporate presentation (https://ibn.fm/X6cTD). The Fan Pass Live app is available on Google Play and the Apple Store. You can follow Fan Pass Live on Instagram at @fanpasslive – where the latest information on artist contests and promotions is available. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Global drug delivery innovator Lexaria Bioscience is researching the ability of its patented DehydraTECH(TM) technology to improve the performance of a number of prescription drugs
• Lexaria is a world leader in the investigation of a DehydraTECH-processed cannabidiol (“CBD”) to potentially treat high blood pressure (hypertension), and study outcomes thus far have rendered positive results on effectiveness and patient tolerance
• The company is building a scorecard of data to support its planned FDA application for formal, registered clinical testing under the Investigational New Drug (“IND”) process
• Lexaria recently completed all data analyses of its HYPER-H21-3 study examining DehydraTECH-CBD’s ability to reduce pulmonary artery systolic pressure, and launched HYPER-H21-4 to gather a variety of data points related to DehydraTECH-CBD’s use over a more extensive period of time

High blood pressure has long been labeled “the silent killer” because of its propensity to lead to incapacitating or prematurely deadly strokes, heart attacks and other serious disease indications without necessarily foreshadowing pain or great discomfort. According to the World Health Organization (“WHO”), an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension but only about 1 in 5 (21 percent) people with the condition have it under control with medical treatment (https://ibn.fm/uMZNh). During the past decade within the United States, about 49 percent of the population reported taking at least one prescription medication in the past 30 days in data sampling collected by the National Center for Health Statistics of the Centers for Disease Control and Prevention at selected times, while 24 percent of the individuals took three or more prescriptions and 13 percent took five or more (https://ibn.fm/apjBj). The data showed a marked increase over those persons sampled during the late 1980s to mid-1990s, particularly where multiple medications were concerned. And yet, a recent news report states that as few as 50 percent of patients take their medications exactly as prescribed (https://ibn.fm/ggwCv). Global drug delivery innovator Lexaria Bioscience (NASDAQ: LEXX) is devoting its research and product development to making drug substances more effective in their approach to treating medical conditions such as high blood pressure and, in the process, to overcoming many of the obstacles that may hinder their proper use by patients. The company’s patented DehydraTECH(TM) technology combines an active pharmaceutical ingredient (“API”) with a fatty acid oil and performing a patented dehydration synthesis process before ingestion The Company has demonstrated significant improvements of absorption into bloodstream and even into brain tissue, in as little as minutes after ingestion. One area of Lexaria’s research has focused on pursuing U.S. Food and Drug Administration (“FDA”) approval to begin formal, registered clinical testing of its DehydraTECH-processed cannabidiol (“CBD”) for the treatment of hypertension under the Investigational New Drug (“IND”) process. Lexaria recently announced the launch of its HYPER-H21-4 randomized, double blinded, placebo-controlled, cross-over study of DehydraTECH-CBD in relation to  hypertension, with the potential for enhancing Lexaria’s ability to treat cardiovascular and other disease states beyond hypertension that are related to increased arterial stiffness (https://ibn.fm/F1N9A). Lexaria has already completed other human studies. Last year, studies HYPER-H21-1 (https://ibn.fm/30edj) and HYPER-H21-2 (https://ibn.fm/RGDrr) provided evidence that DehydraTECH-CBD successfully reduced blood pressure in similarly hypertensive human volunteers, and Lexaria announced earlier this month that it had completed all data analyses of its HYPER-H21-3 study with positive safety and efficacy findings (https://ibn.fm/HS9sV). HYPER-H21-3 used a placebo-controlled and double-blinded design with 16 volunteers, safely simulating hypoxia conditions (reduced oxygen availability) to induce lung artery constriction, or pulmonary hypertension, to analyze the ability of DehydraTECH-CBD to reduce pulmonary artery systolic pressure. HYPER-H21-4 will include 60 people and will be the most comprehensive study Lexaria has conducted to date. Dosing in more than half the volunteers has already begun and all treatment visits are expected to be finished by early July. The volunteers are between the ages of 40 and 70 with documented or measured elevated blood pressure, mild hypertension or moderate (stage 2) hypertension. The participants will use an escalating dose of DehydraTECH-CBD every day for a 5-week duration, establishing data for DehydraTECH-CBD’s extended use over time and providing secondary data outcomes that may ultimately lead to additional applications for DehydraTECH-CBD, according to the company. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Delic is a leader in new medicines and treatments that offers education, research, high-quality products, and treatment options
• The company is on a mission to help heal the mental health pandemic, which has been triggered and worsened by the COVID-19 disease
• Delic operates the largest, most profitable chain of wellness clinics providing ketamine treatments in the United States
• With 13 clinics already in operation, Delic is eyeing expansion as it seeks to ensure 60-70% of Americans are within a 45-minute drive to its clinics

The latest data from the World Health Organization (“WHO”) shows that the COVID-19 pandemic has triggered a 25% increase in the number of cases of anxiety and depression globally. Caused by multiple exacerbating factors, including loneliness, suffering and death, fear of infection, financial worries, and grief, this increased prevalence has also coincided with the substantial disruption in mental health services, creating a gaping hole in the care of people leaving with these conditions (https://ibn.fm/Tzpcj). Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, has stepped up its efforts as it looks to fill the gaps exposed by COVID-19’s battering of the health sector. “Our mission is to heal the planet. We want to help heal the mental health pandemic. I don’t think we could have come about at a better time. I think it’s necessary; I wish it weren’t so necessary, but it is, and so, when people need that help, we are here to provide it,” Delic Co-founder and CEO, Matt Stang, said in a January interview (https://ibn.fm/Ycnhe). To fulfill this mission, Delic offers education, through an impressive, assorted portfolio of media offerings, including a wellness event, digital lifestyle magazine, and podcast; research through Delic Labs, a federally-licensed cannabis and psilocybin research lab; and, most importantly, high-quality products and treatment options through wellness clinics operating under the Ketamine Wellness Centers brand. The company currently operates 13 wellness clinics across nine states, making it the owner of the largest, most profitable chain of wellness clinics in the United States. Looking ahead, Delic plans to maintain this lead with plans to open more clinics in multiple other locations. Ultimately, according to Stang, the company’s long-term vision for this expansion drive is to have 60-70% of the American population within a 45-minute drive to the clinics. The expansion is also strategic in other ways. During the interview, Stang estimated that some psychedelic substances such as MDMA (ecstasy) and psilocybin could receive “some form of approval” within the next one to two years, with other compounds slated for possible legal availability in the subsequent years. Accordingly, Delic is positioning its clinics to be the go-to wellness centers for patients once the nascent psychedelic drugs are finally available. “[Once the psychedelic drugs have received some form of FDA approval] Delic will be the place you can go – you’ll have a clinic in your backyard that you go to for psychedelic medicine treatment, just like any other type of pharmaceutical,” Stang explained. He further noted that the clinics will offer psychedelic medicine treatment on an in-person basis, where qualified professionals will sit with patients and walk them through the process, offering them the efficacy they seek and, as a result, helping them change their minds and lives. Through the Ketamine Wellness Centers, Delic is providing a scalable, trusted, and accessible network of psychedelic clinics with a repeatable, non-habit forming, and effective treatment process. The clinics, coupled with its research and development division, put the company at the center of the burgeoning psychedelics and mental health treatment industries. According to an Open Minds Market Intelligence Report, the spending on mental health treatment and services grew 52.1% between 2009 and 2019, reaching $225 billion (https://ibn.fm/dZpEf). Separately, the global psychedelic drugs market is expected to grow robustly at a CAGR of 14.5% between 2021 and 2026, from $3.21 billion to $6.33 billion (https://ibn.fm/uC6nJ). For more information, visit the company’s website at www.DelicCorp.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF